PICK1 Antibody

What is PICK1 and why are antibodies against it important for research?

PICK1 (Protein Interacting with C Kinase 1) is a scaffold protein that functions as an adapter protein, binding and organizing the subcellular localization of various membrane proteins containing PDZ recognition sequences. PICK1 plays crucial roles in:

• Synaptic plasticity through regulation of AMPA receptor trafficking and internalization

• Actin polymerization inhibition by interfering with Arp2/3 complex activity

• Regulation of astrocyte morphology

• Insulin production and maintenance of pancreatic beta cells

PICK1 antibodies are essential tools for studying these diverse functions across multiple tissues, particularly in neuroscience, metabolism, and cancer research. They enable visualization, quantification, and characterization of PICK1 expression patterns, protein-protein interactions, and subcellular localization .

What are the typical molecular weights for PICK1 in Western blot detection?

When using PICK1 antibodies in Western blot applications, researchers should expect to detect bands at approximately:

• 46-47 kDa (calculated molecular weight)

• 40-52 kDa (observed range depending on sample type and post-translational modifications)

For example, ab3420 shows bands at approximately 40 kDa and 52 kDa in transfected CHO cells expressing human PICK1 . The Proteintech PICK1 antibody (67099-1-Ig) shows a band at 50 kDa . This variation reflects potential post-translational modifications or splice variants that researchers should account for when interpreting their results.

Which species reactivity should I consider when selecting a PICK1 antibody?

Most commercially available PICK1 antibodies demonstrate reactivity across multiple mammalian species due to high sequence conservation. When selecting an antibody, consider:

The antibody selection should be guided by the specific species being studied and the planned application .

How can PICK1 antibodies help elucidate the role of PICK1 in AMPA receptor trafficking?

PICK1 plays a critical role in activity-dependent AMPAR trafficking, particularly during synaptic plasticity events. Research has established that:

PICK1 functions as an endocytic accessory protein that associates with clathrin-coated pits (CCPs) and is required for NMDAR-dependent targeting of GluA2-containing AMPARs. To effectively study this process:

• Use immunoprecipitation with PICK1 antibodies to identify protein complexes with AMPAR subunits and endocytic machinery components

• Employ immunofluorescence with PICK1 antibodies to track the co-localization of PICK1 with GluA2/3 subunits during NMDA receptor stimulation

• Combine with live-cell imaging using fluorescently tagged PICK1 constructs to visualize trafficking dynamics

Particularly informative is the use of PICK1 antibodies in neurons before and after NMDA treatment to visualize the translocation of PICK1-AMPAR complexes from the plasma membrane to endocytic vesicles .

What is the significance of PICK1-PACSIN interaction in research, and how can antibodies help study it?

The PICK1-PACSIN interaction represents a critical molecular mechanism in AMPAR endocytosis and synaptic plasticity. Research has shown that:

• PICK1 directly interacts with all three members of the PACSIN family (PACSIN1-3)

• The interaction is regulated by PACSIN phosphorylation within its variable region

• This interaction is required for AMPAR endocytosis and cerebellar long-term depression

To study this interaction:

• Use co-immunoprecipitation assays with PICK1 antibodies to pull down PACSIN proteins from brain lysates

• Employ proximity ligation assays with specific antibodies to both proteins to visualize their interactions in situ

• Combine with mutational analysis of the binding domains to map the interaction interfaces

Studies have shown that disrupting this interaction using either PACSIN1 knockdown or phosphomimetic mutations of PACSIN2 inhibits AMPAR endocytosis and eliminates cerebellar long-term depression , highlighting the importance of this complex in synaptic plasticity mechanisms.

How are PICK1 antibodies used to investigate its role in disease models?

PICK1 has been implicated in various pathological conditions, with antibodies providing crucial insights:

• Diabetes Research:

  • PICK1 is essential for proinsulin processing and insulin secretion

  • In pancreatic beta cells, PICK1 forms complexes with ICA69 in immature secretory granules

  • PICK1 antibodies can detect depleted PICK1 in islets from conditional knockout mice with impaired glucose tolerance

• Cancer Studies:

  • PICK1 overexpression correlates with histological grade, lymph node metastasis, and Her-2/neu-positivity in breast cancer

  • PICK1 expression can be detected using immunohistochemistry with specific antibodies (1:75 dilution)

  • In nasopharyngeal carcinoma, PICK1 inhibits malignancy by inactivating the Wnt/β-catenin signaling pathway

• Neurodegenerative Disorders:

  • PICK1 dysregulation is implicated in Alzheimer's and Parkinson's diseases

  • Antibodies allow for detection and analysis of PICK1 levels in different cell types and brain regions

What are the optimal conditions for using PICK1 antibodies in Western blotting?

For optimal Western blot results with PICK1 antibodies, consider these methodological details:

Sample Preparation:

• Brain tissue, neuronal cultures, or cell lines expressing PICK1 (e.g., CHO, LNCaP, MCF-7)

• 20-30 μg total protein per lane for cell lysates

• Use RIPA buffer with protease inhibitors for extraction

Blocking and Antibody Incubation:

Detection System:

• HRP-conjugated secondary antibodies (typically 1:10,000 dilution)

• ECL detection with 2-3 minute exposure time for optimal visualization

How should I optimize immunofluorescence experiments with PICK1 antibodies?

Successful immunofluorescence with PICK1 antibodies requires careful optimization:

Fixation and Permeabilization Options:

• Paraformaldehyde (4%) followed by permeabilization with:

  • 0.1% saponin in PBS (for better preservation of membrane structures)

  • 0.5% Triton X-100 (for stronger permeabilization)

Antibody Dilutions and Incubation:

Secondary Antibody Selection:

• For rabbit primary antibodies: Alexa Fluor 488-conjugated goat anti-rabbit (1:500)

• For mouse primary antibodies: Alexa Fluor 555-conjugated donkey anti-mouse (1:1000)

Visualization Tips:

• PICK1 typically shows perinuclear staining with punctate distribution in neuronal processes

• Look for colocalization with synaptic markers to confirm specificity

What controls should I include when validating PICK1 antibodies?

Proper validation of PICK1 antibodies requires several critical controls:

Positive Controls:

• Brain tissue (particularly hippocampus) or neuronal cultures where PICK1 is highly expressed

• Cell lines transfected with PICK1 expression constructs (e.g., CHO cells expressing human PICK1)

• Specific cell types known to express high levels (e.g., MDA-MB-231 for breast cancer studies)

Negative Controls:

• PICK1 knockout tissues or cells (as demonstrated with U-87 MG PICK1 knockout cell line)

• Isotype control antibodies (e.g., rabbit IgG monoclonal [EPR25A])

• Primary antibody omission to detect non-specific secondary antibody binding

Validation Techniques:

• Western blotting to confirm specificity at the expected molecular weight

• siRNA/shRNA knockdown to demonstrate antibody specificity (e.g., syntabulin shRNA #1)

• Comparison of multiple antibodies targeting different epitopes of PICK1

• Pre-adsorption of antibody with immunizing peptide to block specific binding

Why might I observe multiple bands when using PICK1 antibodies in Western blot?

Multiple bands in PICK1 Western blots can occur for several reasons:

• Post-translational modifications:

  • Phosphorylation of PICK1 after PKC activation

  • Other modifications affecting protein mobility

• Protein-protein interactions:

  • Incomplete sample denaturation leading to detection of PICK1 complexes

  • PICK1 interacts with multiple partners (e.g., GluA2/3, PACSIN1-3)

• Proteolytic degradation:

  • Sample preparation without sufficient protease inhibitors

  • Freeze-thaw cycles causing protein degradation

• Antibody specificity issues:

  • Cross-reactivity with related proteins containing PDZ or BAR domains

  • Non-specific binding to highly abundant proteins

Methodological solutions:

• Include phosphatase inhibitors if phosphorylated forms are suspected

• Use stronger denaturing conditions (increase SDS concentration to 2%)

• Prepare fresh samples with complete protease inhibitor cocktails

• Compare results with alternative PICK1 antibodies targeting different epitopes

How can I address weak or non-specific PICK1 antibody staining in immunohistochemistry?

To improve PICK1 antibody performance in immunohistochemistry:

For weak signal:

• Optimize antigen retrieval:

  • Modify microwave treatment (5-min high-power followed by 10-min low-power in PBS, pH 7.0)

  • Try citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for alternative epitope exposure

• Increase antibody concentration:

  • Titrate antibody (e.g., 1:75 to 1:50 dilution for polyclonal antibodies)

  • Extend primary antibody incubation time (overnight at 4°C)

• Enhance detection sensitivity:

  • Use polymer-based detection systems

  • Employ tyramide signal amplification

For non-specific staining:

• Optimize blocking:

  • Increase blocking time (2 hours at room temperature)

  • Use alternative blocking agents (5% BSA, 10% normal serum)

• Reduce background:

  • Include 0.1-0.3% Triton X-100 in antibody diluent

  • Add 0.1% Tween-20 to wash buffers

  • Include additional washing steps (5x5 minutes)

How should I interpret differences in PICK1 detection between different experimental models?

Interpreting variations in PICK1 detection across experimental models requires careful consideration:

• Expression level differences:

  • PICK1 expression varies by tissue (highest in brain and testis)

  • Cell-type specific expression patterns (neurons vs. astrocytes)

  • Disease states may alter expression (upregulated in breast cancer by 41.23%)

• Subcellular localization variations:

  • Different fixation methods may preserve distinct subcellular compartments

  • PICK1 localization changes during stimulation (e.g., NMDA receptor activation)

  • Coexpression with binding partners (syntabulin) affects PICK1 clustering and axonal targeting

• Post-translational modifications:

  • Phosphorylation state affects antibody binding and protein function

  • Cellular activation changes modification patterns

Analytical approach:

• Compare relative rather than absolute expression levels between models

• Include multiple detection methods (WB, IF, IP) for comprehensive analysis

• Use subcellular fractionation to separate membrane, cytosolic, and nuclear fractions

• Correlate PICK1 expression/localization with functional readouts specific to the cellular process being studied

How can PICK1 antibodies be used to study the protein's role in insulin production?

Recent research has revealed PICK1's critical role in insulin production, with antibodies being instrumental in these discoveries:

• Colocalization studies:

  • Use double immunofluorescence with PICK1 antibodies and insulin/proinsulin antibodies

  • Track the association of PICK1 with secretory granules in pancreatic beta cells

• Secretory granule isolation:

  • Employ subcellular fractionation followed by Western blotting with PICK1 antibodies

  • Quantify PICK1 association with different maturation stages of insulin granules

• Conditional knockout analysis:

  • Use PICK1 antibodies to confirm selective PICK1 depletion in pancreatic beta cells

  • Compare PICK1 levels in isolated islets, pancreas, brain, and other tissues

Research has shown that beta cell-specific PICK1-knockout mice exhibit impaired glucose tolerance, profound insulin deficiency, and elevated proinsulin levels, indicating PICK1's role in proinsulin processing and insulin secretion. PICK1 antibodies have been crucial in demonstrating the specific depletion of PICK1 protein in islets isolated from conditional knockout mice .

What strategies can be employed to study PICK1's dual role in tumor biology?

PICK1 exhibits context-dependent roles in cancer biology, functioning as both an oncogene and tumor suppressor:

• In breast cancer:

  • PICK1 overexpression correlates with poor prognosis

  • Use immunohistochemistry with PICK1 antibodies to assess correlation with histological grade and lymph node metastasis

  • Combine with Her-2/neu, ER, and PR staining for molecular subtyping

• In nasopharyngeal carcinoma:

  • PICK1 functions as a tumor suppressor

  • Use Western blotting to confirm PICK1 knockdown or overexpression in cell lines

  • Track effects on migration, invasion, and proliferation

• Mechanistic studies:

  • Employ co-immunoprecipitation with PICK1 antibodies to identify binding partners in cancer cells

  • Use immunofluorescence to track subcellular localization changes during cancer progression

  • Combine with Wnt/β-catenin pathway component antibodies to study signaling interactions

These contradictory functions highlight the importance of tissue-specific context in PICK1 biology, with antibodies providing crucial tools for distinguishing its roles across different cancer types .

How can emerging techniques enhance PICK1 antibody applications in neuroscience?

Cutting-edge methodologies are expanding the utility of PICK1 antibodies in neuroscience research:

• Super-resolution microscopy:

  • Use STORM or PALM imaging with fluorescently-labeled PICK1 antibodies

  • Resolve PICK1 nanodomains at synapses with 10-20nm precision

  • Track dynamic changes in PICK1-AMPAR complexes during synaptic plasticity

• Proximity labeling approaches:

  • Combine PICK1 antibodies with proximity ligation assays to visualize specific protein-protein interactions

  • Use APEX2-PICK1 fusion proteins with subsequent antibody detection to map the PICK1 interactome

• Live-cell imaging:

  • Complement antibody studies with fluorescently tagged PICK1 for dynamic trafficking analysis

  • Correlate fixed-cell antibody staining with live patterns to validate observations

• Tissue clearing techniques:

  • Apply CLARITY or iDISCO with PICK1 antibodies for whole-brain mapping of PICK1 distribution

  • Study regional and cell-type specific expression patterns in disease models

These approaches extend beyond traditional applications, enabling researchers to address previously inaccessible questions about PICK1's spatial organization and temporal dynamics in neuronal function .